Effect of Ayurveda Spice Mix Tablet for the Prevention of COVID-19 infection in people exposed to Covid 19 and in high risk patients

"Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel/High-Risk patientsâ??

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026674

Enrollment

130

Registered

2020-07-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Ayurveda Spice Mix tablet: Ayurveda Spice mix (Tulsimmune) 500 mg INGREDIENTS 1.Licorice-Glycerrhizaglabra â?? 50mg 2.Tulsi-Ocimum sanctum â?? 100 mg 3.Ginger â?? Zinzber officinalis 40

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18-75 years 2. Health care workers/Covid Fighters like police/Social workers etc or high risk group patients in public/private hospitals in India or People in areas of risk of SARS-CoV-2 transmission. 3. People exposed to Covid 19 or having Contact history in 14 days 4. Understanding of the aim of the study and, therefore,acknowledging they have not been on any drug aiming atpre exposure prophylaxis against SARS-CoV-2 (COVID-19) since 1st of May 2020 untill 7 days before the study. This also includes drug forHIV. 5. Negative pregnancy test during the previous 7 days to start treatments or more than 2 years after menopause

Exclusion criteria

Exclusion criteria: 1. COVID + Ve Patient with Symptoms of pneumonia/Hospitalized 2. Active hepatitis B infection, HIV infection 3. Renal failure with estimated glomerular filtration rate (GFR) 4. Participant with any immunosuppressive condition or hematological disease 5. Breastfeeding 6. Known allergy to any of the medication used in this trial

Design outcomes

Primary

Measure	Time frame
Reducing number of infected patients in health professionals /workers, Covid fighters like police, social workers etc and people exposed Covid 19 or having history of Contact.Timepoint: day 0, day 14, day 28	—

Secondary

Measure	Time frame
1. Reduction in numbers of patients and duration of symptoms measured in days and severity of Symptoms of SARS-CoV-2 (COVID-19) confirmed infected participants of SARS-CoV-2 (COVID-19 2. Reduction in clinical severity of SARS CoV2 by SpO2%, Temperature, BP etc, Lab testing and Pulmonay Imaging if any Timepoint: 1. Reducing Duration of Symptoms in day 0, day 14, day 28 2. Change is Spo2%, Temp, BP, Lab testing and Pulmonary Imaging If anyday 0, day 14, day 28	—

Measure

Time frame

1. Reduction in numbers of patients and duration of symptoms measured in days and severity of Symptoms of SARS-CoV-2 (COVID-19) confirmed infected participants of SARS-CoV-2 (COVID-19 2. Reduction in clinical severity of SARS CoV2 by SpO2%, Temperature, BP etc, Lab testing and Pulmonay Imaging if any Timepoint: 1. Reducing Duration of Symptoms in day 0, day 14, day 28 2. Change is Spo2%, Temp, BP, Lab testing and Pulmonary Imaging If anyday 0, day 14, day 28

—

Countries

India

Contacts

Public ContactDr Manoj Chaudhari

Ashtang Ayurveda Mahavidyalaya

drgmarda@gmail.com9372009589

Outcome results